公开(公告)号：US11753412B2

公开(公告)日：2023-09-12

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade—Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61K31/5517 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

CPC classification number: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20210309662A1

公开(公告)日：2021-10-07

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20210284649A1

公开(公告)日：2021-09-16

申请号：US16325080

申请日：2017-08-16

Applicant: UWM Research Foundation, Inc. ,  The Trustees of Columbia University in the City of New York

Inventor： Alexander E. Arnold ,  Douglas C. Stafford ,  James M. Cook ,  Charles W. Emala ,  Gloria Forkuo ,  Rajwana Jahan ,  Revathi Kodali ,  Guanguan Li ,  Michael Rajesh Stephen

IPC: C07D487/14 ,  A61P11/06 ,  C07D487/04

Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.

公开(公告)号：US20190300534A1

公开(公告)日：2019-10-03

申请号：US16283926

申请日：2019-02-25

Applicant: UWM Research Foundation, Inc.

Inventor： James M. Cook ,  Michael Ming-Jin Poe ,  Kashi Reddy Methuku ,  Guanguan Li

IPC: C07D487/04

Abstract: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.